172 related articles for article (PubMed ID: 34589924)
1. Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors.
Kasparian S; Gentille C; Burns E; Bernicker EH
JTO Clin Res Rep; 2020 Jun; 1(2):100017. PubMed ID: 34589924
[TBL] [Abstract][Full Text] [Related]
2. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
3. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
6. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
[TBL] [Abstract][Full Text] [Related]
9. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
[TBL] [Abstract][Full Text] [Related]
11. Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report.
Zhang Y; Yang J; Shao T; Chen J; Shu Q; Shou L
Hum Vaccin Immunother; 2024 Dec; 20(1):2313281. PubMed ID: 38348622
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report.
Wang X; Mi X; Li T; Li C
Exp Ther Med; 2023 May; 25(5):228. PubMed ID: 37114179
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.
Tanaka Y; Matsubara O; Asada K; Muramatsu A; Suzuki M; Shirai T
Respir Med Case Rep; 2019; 28():100885. PubMed ID: 31249779
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.
Liu X; Qiao L
Front Nutr; 2022; 9():810472. PubMed ID: 35399666
[TBL] [Abstract][Full Text] [Related]
15. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports.
Lin Z; Liu Q; Wei Q; Lin L; Chen X; Xue D
Ann Transl Med; 2020 Sep; 8(17):1100. PubMed ID: 33145319
[TBL] [Abstract][Full Text] [Related]
18. The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Li J; Xiang C; Wang Y; Zhou Y; Cao S; Ling X; Ye J; Zheng J; Shao L; Zhong H; Han Y
Ann Transl Med; 2021 May; 9(9):779. PubMed ID: 34268392
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.
Alkader M; Altaha R; Alkhatib L; Jabali EH; Alsoreeky MS
Cureus; 2022 Oct; 14(10):e30194. PubMed ID: 36381823
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report.
Chan KH; Lakkasani S; Ramahi A; Shaaban HS
Cureus; 2020 Apr; 12(4):e7764. PubMed ID: 32455081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
